Previously, the treatment options for these two subtypes of NSCLC were historically similar.8 In 2004, two studies found out that a subgroup of NSCLC patients with specific mutations in the epidermal growth factor receptor (EGFR) gene were correlated with clinical responses to the tyrosine-kinase inhibitor (TKI) gefitinib.9,10 These findings ushered in a widening divide in the management of these two diseases. Here, EGFR is linked to non-small cell lung carcinoma.